

CELL THERAPEUTICS INC
Form POS AM
March 16, 2009

As filed with the Securities and Exchange Commission on March 16, 2009

Registration No. 333-131533

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM S-3
(Post-Effective Amendment No. 2)
REGISTRATION STATEMENT

UNDER
THE SECURITIES ACT OF 1933

CELL THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Edgar Filing: CELL THERAPEUTICS INC - Form POS AM

(State of other jurisdiction of
incorporation or organization)

(Primary Standard Industrial
Classification Code Number)
501 Elliott Avenue West, Suite 400

(I.R.S. Employer
Identification No.)

Seattle, Washington 98119

(206) 282-7100

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

James A. Bianco, M.D.

Chief Executive Officer

Cell Therapeutics, Inc.

501 Elliott Avenue West, Suite 400

Seattle, Washington 98119

(206) 282-7100

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copy to:

Karen A. Dempsey, Esq.

Orrick, Herrington & Sutcliffe LLP

405 Howard Street

San Francisco, California 94105

(415) 773-5700

Approximate date of commencement of proposed sale to the public: N/A

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, check the following box.

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

Edgar Filing: CELL THERAPEUTICS INC - Form POS AM

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of accelerated filer, large accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer <input type="checkbox"/>	Accelerated filer <input checked="" type="checkbox"/>
Non-accelerated filer <input type="checkbox"/> (Do not check if a smaller reporting company)	Smaller reporting company <input type="checkbox"/>

EXPLANATORY NOTE

This Post-Effective Amendment No. 2 to the Registration Statement on Form S-3 is being filed, pursuant to the Registrant's undertaking in Part II, Item 17(a)(3) of the original Registration Statement, for the purpose of removing from registration \$6,000,000 of Series C 10% Convertible Senior Notes (the "Notes") and 43,795,620 shares of common stock issuable upon conversion of the Notes, which Notes and shares of common stock were originally registered for issuance under the Securities Act of 1933.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment No. 2 the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Seattle, state of Washington, on March 16, 2009.

CELL THERAPEUTICS, INC.

By: */s/ James A. Bianco*
James A. Bianco, M.D.
Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
*	Chairman of the Board	March 16, 2009
Phillip M. Nudelman, Ph.D.		
<i>/s/ James A. Bianco</i>	Chief Executive Officer and Director (Principal Executive Officer)	March 16, 2009
James A. Bianco, M.D.		
*	Executive Vice President, Finance and Administration (Principal Financial Officer and Principal Accounting Officer)	March 16, 2009
Louis A. Bianco		
*	Director	March 16, 2009
John H. Bauer		
*	Director	March 16, 2009
Vartan Gregorian, Ph.D.		
*	Director	March 16, 2009
Richard L. Love		
*	Director	March 16, 2009
Mary O. Mundinger, Dr. PH		
*	Director	March 16, 2009
Jack W. Singer, M.D.		
*	Director	March 16, 2009
Frederick W. Telling, Ph.D.		

*By: /s/ James A. Bianco
James A. Bianco, M.D.
Attorney-in-Fact